A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Open Access
- 31 May 2006
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 9 (5), 341-349
- https://doi.org/10.1016/j.ccr.2006.03.029
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- PI 3-kinase p110β: a new target for antithrombotic therapyNature Medicine, 2005
- Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B InhibitorsCancer Research, 2005
- Phosphoinositide 3-Kinase Catalytic Subunit Deletion and Regulatory Subunit Deletion Have Opposite Effects on Insulin Sensitivity in MiceMolecular and Cellular Biology, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- DNA Repair: The Importance of Phosphorylating Histone H2AXCurrent Biology, 2005
- Dysregulation of the TSC-mTOR pathway in human diseaseNature Genetics, 2004
- Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populationsProceedings of the National Academy of Sciences of the United States of America, 2004
- The PIK3CA gene is mutated with high frequency in human breast cancersCancer Biology & Therapy, 2004
- New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathwayProceedings of the National Academy of Sciences of the United States of America, 1999
- The SH2 Domain-containing Inositol 5′-Phosphatase (SHIP) Recruits the p85 Subunit of Phosphoinositide 3-Kinase during FcγRIIb1-mediated Inhibition of B Cell Receptor SignalingOnline Journal of Public Health Informatics, 1999